Organization: MDS Nordion

MDS partners to develop new medical imaging tracer

MDS Nordion is collaborating with two French firms to develop new positron emission tomography (PET) radiotracers for cancer diagnostics using Gallium-68. The project between Guerbet (a pharmaceutical firm wholly dedicated to medical imaging) and Cyceron (a public research organization backed by several French research institutes) has the full support Eureka, an massive intergovernmental initiative aimed…

AECL reactor shutdown to last at least 3 months

The emergency shutdown of the Atomic Energy of Canada Ltd‘s National Research Universal (NRU) reactor at Chalk River ON will last much longer than originally anticipated. The NRU — contracted by MDS Nordion, Kanata ON, to produce the majority of medical isotopes used for medical procedures in North America — will now remain idle for…

MDS Nordion sells off two product lines

Ottawa-based MDS Nordion has sold its beam therapy and self-contained irradiator product lines to Best Medical International Inc, Springfield VA for an undisclosed amount. The move is part of the company’s strategy to focus on molecular medicine. The two product lines sold to Best generate $32 million in revenue and support approximately 150 employees. Best…

MDS Nordion signs pact with Russia’s Rosenergoatom

MDS Nordion has signed a 17-year supply agreement for cobalt-60 with Russia’s Rosenergoatom, the operating utility of Russian nuclear power plants. The contract expands upon a 2005 pact by providing an increased supply of cobalt-60 until 2024. The agreement will boost MDS’s supply by 30% by 2016. Cobalt-60 is used primarily to sterilize hospital medical…

MDS Nordion invests in U of O imaging centre

MDS Nordion is investing $2.2 million in a Molecular Imaging Centre of Excellence at the Univ of Ottawa Heart Institute. Slated to open later this year, the Centre will see the two organizations collaborate on joint cardiology research. The Centre will also be made available to large pharmaceutical organizations requiring molecular imaging technology to accelerate…

MDS Nordion teams with Avid Radiopharmaceuticals

MDS Nordion, Ottawa, is collaborating with Avid Radiopharmaceuticals Inc, Philadelphia PA, to conduct clinical trials for Avid’s radiopharmaceuticals designed to diagnose and monitor Alzheimer’s disease. MDS Nordion will radiolabel Avid compounds for use in proof-of-concept clinical trials for Avid’s single proton emission computed tomography (SPECT) molecular imaging technology….

MDS Inc scales back, sharpens core focus

MDS Inc has announced a major overhaul of its various business lines that sees a reduction in its divisions to focus on its core life sciences activity, layoffs of 500 employees and a focus on near-term improvement of financial performance. MDS will retain MDS Pharma Services (contract research), MDS Nordion (molecular imaging and radio-therapeutics) and…

MDS completes new cyclotron at TRIUMF

MDS Nordion has completed its new $20-million cyclotron in Vancouver where it is co-located with TRIUMF. The cyclotron will begin producing radioisotopes in April, starting with thallium-201, which is used as a heart imaging agent. The cyclotron will double MDS Nordion’s production capacity and result in 20 new jobs….

MDS Nordion sells oncology software unit to Delft

MDS Nordion has sold its Oncology Software Solutions (OSS) business unit to a Dutch firm for $35 million. The unit was purchased by Delft Instruments NV and will be integrated into its Nucletron BV subsidiary. OSS has built a suite of oncology software products and services under its Oncentra brand. MDS said the OSS will…